Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that in collaboration with the American Society of Clinical Oncology (ASCO), the academic research community now has access to a dataset of 500 Glioblastoma patients with matched molecular and clinically data....
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus's TIME Trial® Network and the companies...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its expansion into infectious diseases, starting with COVID-19. Tempus is leveraging its existing capabilities to launch a diagnostic polymerase chain reaction (PCR) test, as well as a broad-based, healthcare operations...
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its new prospective, pharmacogenomics study in psychiatry. The observational study aims to demonstrate the need for more transparent and reliable access to public data specific to a patient’s pharmacogenetic...